Recently, a study involving several BlCa cell lines reported that BlCa cells resistant to cisplatin chemotherapy with high HOXA9 promoter methylation levels were sensitized to cisplatin after treatment with 5-aza-2′-deoxycytidine alone or in combination with the HDAC inhibitor vorinostat (Xylinas et al., 2016). The gene discussed is HDAC9; the disease is bladder transitional cell carcinoma.